gms | German Medical Science

59th Annual Meeting of the German Society of Neurosurgery (DGNC)
3rd Joint Meeting with the Italian Neurosurgical Society (SINch)

German Society of Neurosurgery (DGNC)

1 - 4 June 2008, Würzburg

Impressive tumor response to therapy with Bevacizumab and Irinotecan – an option in recurrent glioblastoma

Beeindruckende Tumorrückbildung unter Bevacizumab und Irinotecan – eine Therapieoption bei rezidivierendem Glioblastom

Meeting Abstract

  • corresponding author Á. Oszvald - Neurochirurgische Klinik, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main
  • E. Hattingen - Institut für Neruroradiologie, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main
  • V. Seifert - Neurochirurgische Klinik, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main
  • K. Franz - Neurochirurgische Klinik, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main

Deutsche Gesellschaft für Neurochirurgie. Società Italiana di Neurochirurgia. 59. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie e.V. (DGNC), 3. Joint Meeting mit der Italienischen Gesellschaft für Neurochirurgie (SINch). Würzburg, 01.-04.06.2008. Düsseldorf: German Medical Science GMS Publishing House; 2008. DocSO.01.02

The electronic version of this article is the complete one and can be found online at:

Published: May 30, 2008

© 2008 Oszvald et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Objective: We report on four patients with recurrent glioblastoma following repeated treatment for multiple recurrences. Confronted with another recurrence, a treatment with Bevacizumab and Irinotecan according to the phase II study of Friedman et al. (2007) was given to the patients as ultima ratio therapy.

Methods: All four patients with primary and secondary glioblastoma were treated in our clinic during their course of disease. Treatment of recurrences after standard therapy was discussed individually in every case, including reoperation, reiraddiation, brachytherapy and different chemotherapeutic protocols. Clinical deterioration and new neurological deficits corresponded with progressive tumor in magnetic resonance imaging (MRI).

Results: Three of our four patients responded with an impressive clinical improvement within four weeks. The first MRI control in these three patients showed a stable disease level in one and a tumor regression in two patients. The patient with stable disease developed clinical worsening corresponding to tumor progression in the MRI three months after onset of therapy. In the other two patients clinical improvement with regression of neurological deficits is continuing until now (4 and 12 months after onset of therapy). The subsequent MRI controls in both patients showed ongoing tumor regression with a decrease in contrast enhancement and a reduction of perifocal edema. Complications and adverse effects of Bevacizumab and Irinotecan did not occur.

Conclusions: In view of these positive results with clinical and MRI improvement, the combination of Bevacizumab and Irinotecan should be considered in recurrent glioblastoma after failure of standard therapy.